Related Experiment Video

Updated: Mar 30, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients

Pablo Coto-Segura1, Ana Batalla2, Daniel González-Fernández2

  • 1Dermatología, Hospital Universitario Central Asturias, Oviedo, Spain; Departamento Medicina, Universidad Oviedo, Oviedo; Spain.

International Immunopharmacology
|November 14, 2015
PubMed

Insights

Genetic variants in the CDKAL1 gene may predict how well Psoriasis patients respond to anti-TNF therapies. Specific CDKAL1 gene variants could help identify patients likely to benefit from these treatments.

Area of Science:

  • Genetics
  • Immunology
  • Dermatology

Background:

  • Psoriasis (Psor) patients exhibit varied responses to anti-TNF biologic drugs.
  • Common variants in the CDKAL1 gene are linked to Psoriasis risk.
  • The influence of these variants on anti-TNF therapy response in Psoriasis is unknown.

Purpose of the Study:

  • To investigate if CDKAL1 gene variants affect anti-TNF treatment response in Psoriasis patients.
  • To determine if specific CDKAL1 single nucleotide polymorphisms (SNPs) correlate with treatment outcomes.

Main Methods:

  • Genotyping of 116 Psoriasis patients (78 responders, 38 non-responders) for CDKAL1 SNPs (rs6908425, rs4712523, rs111739077, rs77152992).
  • Assessing treatment response by a 75% reduction in Psoriasis Area and Severity Index (PASI 75) at 24 weeks.
  • Comparing allele and genotype frequencies between responders and non-responders.

Main Results:

  • Significant differences in allele and genotype frequencies were observed between responders and non-responders.
  • The rs6908425 CC homozygote genotype was significantly more prevalent in responders (72% vs. 45%, p=0.005, OR=3.14).

Conclusions:

  • CDKAL1 gene variants significantly influence the response to anti-TNF therapies in Psoriasis patients.
  • Genotyping CDKAL1 variants may aid in predicting patient response to anti-TNF treatments.
  • Further validation in larger patient cohorts is recommended.
Keywords:
Anti-TNFCDKAL1Gene polymorphismPsoriasis

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

35.0K
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

8.1K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
741
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76